SOUTH SAN FRANCISCO, Calif.,
April 12, 2016 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced
that it will present three scientific posters at the American
Association of Cancer Research meeting in New Orleans, Louisiana from April 16 - 20, 2016. The posters will
provide data from the company's preclinical research projects
focused on the important oncology and immuno-oncology targets,
IRAK, AMPK and MerTK. Rigel plans to partner select preclinical
research programs in the future.
An overview of each project and the corresponding AACR
presentation information follows:
IRAK
Rigel has an active IRAK preclinical research
program aimed at understanding the role that certain inflammatory
signals play in creating malignant changes in cells. IRAKs
are key components in the signal transduction pathways associated
with inflammation in humans. The company's researchers have
identified a family of IRAK4 inhibitors that are potent regulators
of the inflammatory signal and are being evaluated for their
potential utility in treating hematological cancers.
Abstract #: 346
Presentation Title:
Potential role for R191, potent and selective IRAK4 kinase
inhibitor, in treatment of hematological
malignancies
Presentation Date: Sunday, April
17, 1:00pm -
5:00pm
Location: Section 17
Poster Board #: 2
AMPK
AMPK is a master regulator of cellular energy
homeostasis and is an attractive research subject for its role in
the metabolism of certain cancers, and other human diseases.
Rigel has identified several potent direct AMPK activators, and is
evaluating their potential to selectively activate AMPK within
certain cancer cells to make them susceptible to the destructive
properties of chemotherapeutic agents.
Abstract #: 3021
Presentation Title: Development
of small molecule direct AMPK activators for the treatment of
cancer
Presentation Time: Tuesday,
April 19, 8:00am -
12:00pm
Location: Section 17
Poster
Board #: 11
MerTK
Mer is a member of the TAM kinase family (Tyro3,
AXL, Mer) known to provide tumor survival signals and support
immunosuppressive tumor microenvironments. Rigel's research on this
family of receptor tyrosine kinases, also produced the AXL kinase
inhibitor (R428/BGB324) currently in Phase 1 oncology studies with
partner BerGenBio. The subject of the AACR presentation is the
company's work with proprietary, orally delivered small molecules
that block MerTK activity in vivo.
Abstract #: 4869
Presentation Title: Small
molecule inhibitors of the anti-inflammatory TAM receptor
MerTK
Presentation Time: Wednesday, April 20, 8:00am - 12:00pm
Location: Section
22
Poster Board #: 10
About Rigel (www.rigel.com)
Rigel
Pharmaceuticals, Inc. is a clinical-stage biotechnology company
dedicated to the discovery and development of novel, targeted drugs
in the therapeutic areas of immunology, oncology and
immuno-oncology. Rigel's pioneering research focuses on signaling
pathways that are critical to disease mechanisms. The company's
current clinical programs include fostamatinib, an oral spleen
tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical
trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic
anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy
(IgAN). In addition, Rigel has two oncology product candidates in
Phase 1 development with partners BerGenBio AS and Daiichi
Sankyo.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
Media Contact: Susan C. Rogers,
Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com
Logo -
http://photos.prnewswire.com/prnh/20030226/RIGLLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-announces-presentations-at-upcoming-american-association-of-cancer-research-aacr-conference-300249824.html
SOURCE Rigel Pharmaceuticals, Inc.